Autres langues SELLAS Life Sciences Group, Inc.

Actions

SLS

US81642T2096

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 08/10/2026			Varia. 5j.	Varia. 1 janv.
11,26 ^USD	-0,44%		-0,62%	+198,67%

25/09	SELLAS Life Sciences présente des données précliniques démontrant l’activité de SLS009 dans des modèles de cancer du pancréas lors de la conférence 2026 de l’AACR sur le cancer du pancréas	CI
14/09	Les plus fortes baisses en avant-Bourse	MT

Autres langues

25/09	SELLAS Life Sciences Presents Preclinical Data Demonstrating SLS009 Activity in Pancreatic Cancer Models at the 2026 AACR Conference on Pancreatic Cancer
25/09	SELLAS Life Sciences Presents Preclinical Data Demonstrating SLS009 Activity in Pancreatic Cancer Models at the 2026 AACR Conference on Pancreatic Cancer
14/09	Top Premarket Decliners
02/09	SELLAS Life Sciences to Present Preclinical Data on SLS009 in Pancreatic Ductal Adenocarcinoma at the 2026 AACR Conference on Pancreatic Cancer
31/08	Social Buzz: Wallstreetbets Stocks Mixed Premarket Monday; SELLAS Life Sciences to Advance, Tesla to Decline
24/08	Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell Monday; Sellas to Rise, Applied Optoelectronics to Fall
11/08	Sellas Life Sciences Q2 Loss Narrows
11/08	Earnings Flash (SLS) SELLAS Life Sciences Posts Q2 Loss $0.05, vs. FactSet Est of $0.05 Loss
11/08	SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update
11/08	SELLAS Life Sciences Group, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
29/06	Social Buzz: Wallstreetbets Stocks Advance Premarket Monday; SELLAS Life Sciences, Strategy to Open Higher
14/05	SELLAS Life Sciences to Participate in Upcoming Investor Conferences
12/05	SELLAS Life Sciences Group Q1 Loss Narrows
12/05	Earnings Flash (SLS) SELLAS Life Sciences Posts Q1 Loss $0.05, vs. FactSet Est of $0.06 Loss
12/05	SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update
12/05	SELLAS Life Sciences Group, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
23/03	SELLAS Life Sciences Group, Inc.(NasdaqCM:SLS) added to S&P Biotechnology Select Industry Index
19/03	SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update
19/03	SELLAS Life Sciences Group, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
17/03	SELLAS Life Sciences to Present Preclinical Data Highlighting Potent Activity of SLS009 in AML at the 2026 AACR Conference
17/03	Sellas Life Sciences Group Announces Preclinical Data On SLS009 In AML
12/03	Sellas Says First Patient Enrolled in Phase 2 Trial of SLS009 in Acute Myeloid Leukemia
12/03	SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009
12/03	Sellas Life Sciences Group Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009
14/01	SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe